Ignite Creation Date:
2024-05-05 @ 4:46 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00313222
Status:
COMPLETED
Last Update Posted:
2010-02-15
First Post:
2006-04-10
Brief Title:
Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension
Sponsor:
Actelion
Organization:
Actelion
Study Overview
Official Title:
Prospective Randomized Placebo-controlled Double-blind Multicenter Parallel Group Study to Assess the Efficacy Safety and Tolerability of Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension CTEPH
Status:
COMPLETED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The present trial investigates a possible use of oral bosentan which is currently approved for the treatment of symptoms of pulmonary arterial hypertension PAH to patients suffering from inoperable chronic thromboembolic pulmonary hypertension CTEPH because of i peripheral localization of thrombotic material or ii persistent or recurrent pulmonary hypertension after pulmonary endarterectomy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None